WO2005100300A1 - 5-アミノレブリン酸塩、その製造方法及びその用途 - Google Patents
5-アミノレブリン酸塩、その製造方法及びその用途 Download PDFInfo
- Publication number
- WO2005100300A1 WO2005100300A1 PCT/JP2005/005765 JP2005005765W WO2005100300A1 WO 2005100300 A1 WO2005100300 A1 WO 2005100300A1 JP 2005005765 W JP2005005765 W JP 2005005765W WO 2005100300 A1 WO2005100300 A1 WO 2005100300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- aminolevulinic acid
- acid
- acid salt
- aminolevulinic
- Prior art date
Links
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical class NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 title claims abstract description 174
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 21
- -1 2-ethylhexyl group Chemical group 0.000 claims description 74
- 239000007864 aqueous solution Substances 0.000 claims description 63
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 48
- 239000007787 solid Substances 0.000 claims description 38
- XWNWBYZHOAIHTK-UHFFFAOYSA-N 5-amino-4-oxopentanoic acid;phosphoric acid Chemical compound OP(O)(O)=O.NCC(=O)CCC(O)=O XWNWBYZHOAIHTK-UHFFFAOYSA-N 0.000 claims description 36
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 25
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000003729 cation exchange resin Substances 0.000 claims description 17
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 229910017604 nitric acid Inorganic materials 0.000 claims description 16
- ITPNRFQMIYQDNO-UHFFFAOYSA-N 5-amino-4-oxopentanoic acid;nitric acid Chemical compound O[N+]([O-])=O.NCC(=O)CCC(O)=O ITPNRFQMIYQDNO-UHFFFAOYSA-N 0.000 claims description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 150000003460 sulfonic acids Chemical class 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 8
- 229910002651 NO3 Inorganic materials 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- 239000000032 diagnostic agent Substances 0.000 claims description 7
- 229940039227 diagnostic agent Drugs 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 238000002428 photodynamic therapy Methods 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 229940043215 aminolevulinate Drugs 0.000 claims description 3
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical group CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 claims description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 8
- 238000000855 fermentation Methods 0.000 abstract description 6
- 230000004151 fermentation Effects 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 4
- 229950010481 5-aminolevulinic acid hydrochloride Drugs 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- 235000011007 phosphoric acid Nutrition 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 241000196324 Embryophyta Species 0.000 description 21
- 239000002904 solvent Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 17
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 16
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 16
- DMSRJJQJLOCKOW-UHFFFAOYSA-N 5-amino-4-oxopentanoic acid;4-methylbenzenesulfonic acid Chemical compound NCC(=O)CCC(O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 DMSRJJQJLOCKOW-UHFFFAOYSA-N 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000220225 Malus Species 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000004255 ion exchange chromatography Methods 0.000 description 8
- 239000003456 ion exchange resin Substances 0.000 description 8
- 229920003303 ion-exchange polymer Polymers 0.000 description 8
- 150000003016 phosphoric acids Chemical class 0.000 description 8
- 229910001961 silver nitrate Inorganic materials 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000000622 irritating effect Effects 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000036556 skin irritation Effects 0.000 description 6
- 231100000475 skin irritation Toxicity 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- JYFHYPJRHGVZDY-UHFFFAOYSA-N Dibutyl phosphate Chemical compound CCCCOP(O)(=O)OCCCC JYFHYPJRHGVZDY-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 125000001287 2,4-xylenyl group Chemical group [H]C1=C(O*)C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 244000291564 Allium cepa Species 0.000 description 3
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000195651 Chlorella sp. Species 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000021016 apples Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000000774 hypoallergenic effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000962 organic group Chemical group 0.000 description 3
- 239000005962 plant activator Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 125000001257 2,5-xylenyl group Chemical group [H]C1=C([H])C(=C(O*)C([H])=C1C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- TUAMRELNJMMDMT-UHFFFAOYSA-N 3,5-xylenol Chemical compound CC1=CC(C)=CC(O)=C1 TUAMRELNJMMDMT-UHFFFAOYSA-N 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KKUKTXOBAWVSHC-UHFFFAOYSA-N Dimethylphosphate Chemical compound COP(O)(=O)OC KKUKTXOBAWVSHC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- LMEMIKWTNPWYMI-UHFFFAOYSA-N acridine half-mustard dihydrochloride Chemical compound Cl.Cl.C1=C(Cl)C=CC2=C(NCCCNCCCl)C3=CC(OC)=CC=C3N=C21 LMEMIKWTNPWYMI-UHFFFAOYSA-N 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229960000781 aminolevulinic acid hydrochloride Drugs 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- WFFZELZOEWLYNK-XPWSMXQVSA-N bis[(e)-octadec-9-enyl] hydrogen phosphate Chemical compound CCCCCCCC\C=C\CCCCCCCCOP(O)(=O)OCCCCCCCC\C=C\CCCCCCCC WFFZELZOEWLYNK-XPWSMXQVSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 2
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000003501 hydroponics Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008635 plant growth Effects 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000000098 2,3-xylenyl group Chemical group [H]C1=C([H])C(=C(C(O*)=C1[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BPRYUXCVCCNUFE-UHFFFAOYSA-N 2,4,6-trimethylphenol Chemical compound CC1=CC(C)=C(O)C(C)=C1 BPRYUXCVCCNUFE-UHFFFAOYSA-N 0.000 description 1
- 125000000577 2,6-xylenyl group Chemical group [H]C1=C([H])C(=C(O*)C(=C1[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- LJKDOMVGKKPJBH-UHFFFAOYSA-N 2-ethylhexyl dihydrogen phosphate Chemical compound CCCCC(CC)COP(O)(O)=O LJKDOMVGKKPJBH-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ABMULKFGWTYIIK-UHFFFAOYSA-N 2-hexylphenol Chemical group CCCCCCC1=CC=CC=C1O ABMULKFGWTYIIK-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WJQOZHYUIDYNHM-UHFFFAOYSA-N 2-tert-Butylphenol Chemical group CC(C)(C)C1=CC=CC=C1O WJQOZHYUIDYNHM-UHFFFAOYSA-N 0.000 description 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- YCSBALJAGZKWFF-UHFFFAOYSA-N anthracen-2-amine Chemical compound C1=CC=CC2=CC3=CC(N)=CC=C3C=C21 YCSBALJAGZKWFF-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- YTFJQDNGSQJFNA-UHFFFAOYSA-N benzyl dihydrogen phosphate Chemical compound OP(O)(=O)OCC1=CC=CC=C1 YTFJQDNGSQJFNA-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BNMJSBUIDQYHIN-UHFFFAOYSA-N butyl dihydrogen phosphate Chemical compound CCCCOP(O)(O)=O BNMJSBUIDQYHIN-UHFFFAOYSA-N 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000010432 cotyledon development Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 102000035124 heme enzymes Human genes 0.000 description 1
- 108091005655 heme enzymes Proteins 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-L methyl phosphate(2-) Chemical compound COP([O-])([O-])=O CAAULPUQFIIOTL-UHFFFAOYSA-L 0.000 description 1
- VOEYXMAFNDNNED-UHFFFAOYSA-N metolcarb Chemical compound CNC(=O)OC1=CC=CC(C)=C1 VOEYXMAFNDNNED-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000000486 o-cresyl group Chemical group [H]C1=C([H])C(O*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- VLYFRFHWUBBLRR-UHFFFAOYSA-L potassium;sodium;carbonate Chemical compound [Na+].[K+].[O-]C([O-])=O VLYFRFHWUBBLRR-UHFFFAOYSA-L 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 101150005573 uvrA gene Proteins 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
Definitions
- the present invention relates to 5-aminolevulinate useful in the fields of microorganisms 'fermentation, animal' medicine, plants and the like, a method for producing the same, a medical composition containing the same, and a plant vital agent containing the same. Relates to the composition.
- Non-Patent Document 1 infectious disease treatment
- Non-Patent Document 2 sterilization, hemophilus diagnosis, derivative raw material, hair removal, rheumatism treatment
- Non-Patent Document 2 sterilization, hemophilus diagnosis, derivative raw material, hair removal, rheumatism treatment
- Non-Patent Document 3 cancer treatment
- Thrombus treatment Non-patent document 4
- Cancer intraoperative diagnosis (Non-patent document 5), Animal cell culture, UV cut, Heme metabolism research, Hair growth, Heavy metal poisoning porphyria diagnosis, Anemia prevention, etc. Is known to be useful for agricultural chemicals.
- 5-aminolevulinic acid is known to be produced only as a hydrochloride, and as raw materials hippuric acid (Patent Document 1), succinic acid monoester chloride (Patent Document 2), furfurylamine (Patent Document 3) A method using hydroxymethylfurfural (Patent Document 4), methyl oxovalerate (Patent Document 5), and succinic anhydride (Patent Document 6) has been reported.
- 5-aminolevulinic acid hydrochloride when directly administered orally to humans or applied to the skin, it has an irritating property that gives a burning sensation to the tongue and skin. Therefore, a 5-aminolevulinic acid salt that is less irritating than 5-aminolevulinic acid hydrochloride is required as 5-aminolevulinic acid used in the field of medicine.
- 5-aminolevulinic acid hydrochloride has a property of partially decomposing at 130 to 156 ° C and completely decomposing at 156 ° C and above, and is difficult to withstand high-temperature heat sterilization. Has a problem.
- Patent Document 7 a sterilization method by radiation irradiation is known (Patent Document 7), but this method requires a radiation irradiation device.
- 5-aminolevulinic acid hydrochloride and silver nitrate may react to cause precipitation of salty silver, which may cause the sprayer nozzle to become clogged and prevent spraying.
- Non-patent Document 6 an aqueous solution containing 5 aminolevulinate ions and nitrate ions has been suggested. 5 Aminolevulinate nitrate has not yet been isolated.
- Patent Document 1 Japanese Patent Laid-Open No. 48-92328
- Patent Document 2 Japanese Patent Laid-Open No. 62-111954
- Patent Document 3 Japanese Patent Laid-Open No. 2-76841
- Patent Document 4 JP-A-6-172281
- Patent Document 5 JP-A-7-188133
- Patent Document 6 JP-A-9-316041
- Patent Document 7 Special Table 2001-514243
- Patent Document 8 Japanese Patent Laid-Open No. 4-338305
- Non-patent literature l Peter W. et. Al, J. Am. Acad. Dermatol, 31, 678-680 (1994)
- Non-patent literature 2 Kenneth T., United States Patent 5, 368, 841 (1994)
- Non-Patent Document 3 Hillemanns P. et. Al., Int. J. Cancer, 85, 649-653 (2000)
- Non-Patent Document 4 Ichiro Yamada et. Al, Abstracts of the Japanese Society for Plastic Surgery (1988)
- Non-Patent Document 5 Kamasaki N. et. Al., Journal of Japanese Society for Laser Medicine 22, 255-262 (2001)
- Non-Patent Document 6 Baxter C.b. et. Al., Toxicology And Applied Pharmacology,
- the present invention provides a novel salt of 5-aminorepric acid that can withstand hypoallergenic or high-temperature heat sterilization treatment, a method for producing the same, a medical composition containing the same, and a plant vitality agent containing the same. It is to provide a composition.
- the present invention relates to the following (1) to (23).
- a 5-aminolevulinic acid salt which is an aminolevulinic acid salt and the salt is at least one selected from the group consisting of a phosphate, a nitrate and a sulfonate.
- R 1 represents a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, an alkenyl group having 2 to 18 carbon atoms, an aralkyl group or a phenyl group having 7 to 26 carbon atoms; n is 0 to 2) of an integer. was only, when n is 2, a plurality of R 1 may be the same or different)
- the 5-aminolevulinic acid salt according to the above (1) which is an aminolevulinic acid phosphate represented by the formula:
- R 1 is a hydrogen atom, a methyl group, an ethyl group, an n-butyl group, a hexadecyl group, a 2-ethylhexyl group, an oleyl group, a benzyl group, or a phenyl group.
- R 2 represents a phenyl group substituted with a lower alkyl group.
- the 5-aminolevulinate according to the above (1) which is a 5-aminolevulinic acid sulfonate represented by the formula:
- a plant vitality composition comprising the 5-aminolevulinate according to any one of (1) to (11) above.
- the 5-aminolevulinic acid salt of the present invention has no odor and no irritating odor. Easy to handle. In addition, since it is hypoallergenic to the skin and tongue and also has good permeability to the skin and the like, it is useful as a photodynamic therapeutic or diagnostic agent for a composition containing it. Furthermore, it has high temperature resistance with a high decomposition point compared with hydrochloride. According to the production method of the present invention, 5-aminolevulinic acid salt can be produced simply and efficiently. In addition, since the salt and salt ion concentration in aqueous solution is low, chlorine damage is unlikely to occur when administered to plants.
- FIG. 1 is a graph showing the relationship between the concentration of 5-aminolevulinate aqueous solution and pH.
- FIG. 2 is a schematic diagram of a dialysis cell.
- FIG. 3 is a graph showing results of porcine skin permeability of 5-aminolevulinic acid phosphate and hydrochloride.
- FIG. 4 is a graph showing the onion skin permeability results of 5-aminolevulinic acid phosphate and hydrochloride.
- the alkyl group having 1 to 18 carbon atoms represented by R 1 may be any of a straight chain, a branched chain or a cyclic chain.
- the linear or branched alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, and a neopentyl group.
- Tert-pentyl group 2-methylbutyl group, n-hexyl group, isohexyl group, 3-methylpentyl group, ethylbutyl group, n-heptyl group, 2-methylhexyl group, n-octyl group, isooctyl group Group, tert-octyl group, 2-ethylhexyl group, 3-methylheptyl group, n-nor group, isonol group, 1-methyloctyl group, ethylheptyl group, n-decyl group, 1-methylnonyl group N-Undecyl group, 1,1-dimethylnonyl group, n-dodecyl group, n-tridecyl group, n-tetradecyl group, n_pentadecyl group, n-hexadecyl group, n-heptadecyl group
- Examples of a cyclic chain or an alkyl group containing a cyclic chain include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a 2-cyclopropylethyl group, and a 2-cyclobutyl group.
- Ethyl group 2-cyclopentylethyl group, cyclohexylmethyl group, 2-cyclohexylethyl group, cycloheptylmethyl group, 2-cyclooctylethyl group, 3-methylcyclohexyl group, 4-methylcyclohexyl group , 4-Ethylcyclohexyl group, 2-Methylcyclohexyl group, 3- (3-Methylcyclohexyl) propyl group, 2- (4-Methylcyclohexyl) ethyl group, 2- (4-Ethylcyclohexyl) ethyl group Group, 2- (2-methylcyclooctyl) ethyl group and the like.
- alkyl group having 1 to 18 carbon atoms a methyl group, an ethyl group, an n-butyl group, an n-hexadecyl group or a 2-ethylhexyl group is particularly preferable, which is preferably an alkyl group having 1 to 16 carbon atoms. Better!/,.
- alkenyl group having 2 to 18 carbon atoms examples include a bur group, a allyl group, an isopropyl group, a 2-butenyl group, a 2-methylaryl group, a 1,1-dimethylaryl group, and a 3-methyl-2 group.
- 5- (4-Ethylcyclohexyl) pentyl group, oleyl group, batasel group, linoleyl group, linoleenyl group and the like can be mentioned, and oleyl group is preferred.
- the aralkyl group having 7 to 26 carbon atoms is preferably composed of an alkyl group having 1 to 6 carbon atoms and an aryl group having 6 to 20 carbon atoms.
- the alkyl group having 1 to 6 carbon atoms include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, and an n-hexyl group.
- aryl group having 6 to 20 carbon atoms examples include phenyl group and naphthyl group. Carbon number? Of the aralkyl groups of ⁇ 26, a benzyl group or a benzyl group is preferred, and a benzyl group is particularly preferred.
- the aryl group of the aralkyl group is an alkyl group having 1 to 6 carbon atoms described above, a methoxy group, an ethoxy group, an n-propoxy group, an n-butoxy group, an isobutoxy group, a tert-butoxy group, or the like.
- substituents such as a halogen atom such as an alkoxy group, a hydroxyl group, an amino group, a nitro group, a cyano group, fluorine, chlorine, bromine or iodine, or a carboxy group.
- a halogen atom such as an alkoxy group, a hydroxyl group, an amino group, a nitro group, a cyano group, fluorine, chlorine, bromine or iodine, or a carboxy group.
- the lower alkyl group that replaces the phenol group represented by R 2 means an alkyl group having 1 to 6 carbon atoms.
- the lower alkyl group is a straight chain, branched chain or cyclic chain. But you can. Examples of linear or branched alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, and neopentyl.
- tert-pentyl group 2-methylbutyl group, n-hexyl group, isohexyl group, 3-methylpentyl group, ethylbutyl group and the like, and methyl group, ethyl group or n-propyl group is preferred.
- a methyl group is particularly preferred.
- the alkyl group containing a cyclic chain include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a 2-cyclopropylethyl group, a 2-cyclobutylethyl group, and the like.
- the substitution position and number of the lower alkyl group are not particularly limited, but the number of substituents is preferably 1 to 3, and particularly preferably 1 or 2.
- Examples of the phenyl group substituted with a lower alkyl group include a phenyl group substituted with an alkyl group having 1 to 6 carbon atoms, specifically, a 2-methylphenol group, 3 -Methylphenyl group, 4-methylphenyl group, 2,3-dimethylphenol group, 2,4-dimethylphenol group, 2,5-dimethylphenol group, 2,6-dimethylphenol group, 3,4_dimethylphenyl group, 3,5-dimethylphenyl group, 2,4,6-trimethylfuryl group, 3,4,5-trimethylfuryl group, 2-ethylfuryl group, tert -Butylphenol group, pentylphenyl group, neopentylphenyl group, hexylphenol group, etc., 4_methylphenol group, 2,4-dimethylphenol group or 2,5-dimethylphenyl group The group is particularly preferred.
- the 5-aminolevulinic acid salt of the present invention may be a solid or a solution.
- the solid may be a force hydrate showing crystals.
- the solution may be a force indicating a state of being dissolved or dispersed in a solvent such as water, the pH of which is adjusted with a pH adjusting agent or the like.
- a solvent such as water
- two or more solvents such as water may be used in combination.
- pH adjusters include buffers using phosphoric acid, boric acid, phthalic acid, succinic acid, succinic acid, tris, acetic acid, lactic acid, tartaric acid, oxalic acid, phthalic acid, maleic acid salts thereof, and the like. Good buffer.
- the solution form of 5-aminolevulinate is preferably an aqueous solution.
- the concentration of 5-aminolevulinate in the aqueous solution is preferably from 0. Olwt ppm to 10 wt%, more preferably from 0.1 wt% to 5 wt%, and particularly preferably from 1 wtppm to lwt%.
- the pH of this aqueous solution is preferably 3 to 7, more preferably 3.5 to 7, and particularly preferably 4 to 7.
- the aqueous solution may contain salts other than the 5-aminolevulinic acid salt of the present invention. In this case, the salt ion concentration is 50 mol of 5-aminolevulinic acid salt.
- the aqueous solution does not contain salt ions.
- the phrase “contains no chloride ions” means that the chloride ion concentration is substantially 0 mol%, that is, the detection limit (0.1 ppm) or less as measured by ion chromatography, for example. preferable.
- the 5-aminolevulinic acid salt of the present invention is produced by eluting 5-aminolevulinic acid adsorbed on a cation exchange resin with an ion-containing aqueous solution and mixing the eluate with phosphoric acids, nitric acid or sulfonic acids. be able to. Moreover, 5-aminolevulinic acid salt can be obtained as a solid by adding a poor solvent to the mixed solution and allowing it to crystallize.
- the 5-aminolevulinic acid adsorbed on the cation exchange resin is not particularly limited, and the purity is not limited.
- JP-A-48-92328, JP-A-62-111954, JP-A-2-76841, JP-A-6-172281, JP-A-7-188133, etc., JP-A-11-42083 Those manufactured according to the method described in the publication No., chemical reaction solutions and fermentation liquids before purification thereof, and commercially available products can also be used. Preferably, 5-aminolevulinic acid hydrochloride is used.
- the cation exchange resin may be either a strong acid cation exchange resin or a weak acid cation exchange resin. Moreover, chelate rosin can also be used conveniently. Of these, strong acid cation exchange resins are preferred.
- the strongly acidic cation exchange resin preferably has a sulfonic acid group bonded to a polystyrene-based resin.
- Adsorption of 5-aminolevulinic acid to the cation exchange resin can be carried out by passing a 5-aminolevulinic acid solution dissolved in a suitable solvent through the cation exchange resin.
- a suitable solvent is not particularly limited as long as 5-aminolevulinic acid dissolves, but water; dimethyl sulfoxide; alcohols such as methanol, ethanol, propanol, isopropanol, butanol, and isobutanol; ⁇ , ⁇ -dimethylformamide, Amides such as ⁇ , ⁇ -dimethylacetamide; pyridines and the like, and water, dimethyl sulfoxide, water or methanol or ethanol are preferred, methanol or ethanol being particularly preferred.
- Two or more solvents may be mixed and used.
- the reaction solvent may be removed or diluted with an appropriate solvent. Note that the solvent, the chemical reaction solution before fermentation, and the fermentation solution may be ⁇ adjusted with the ⁇ adjusting agent.
- the ion-containing aqueous solution used for the elution is not particularly limited. However, phosphoric acid, nitric acid, sulfonic acid, alkali metal or alkaline earth metal hydroxide or carbonate, ammonia, ammine, amino group may be used.
- ammonia is dissolved in water.
- These aqueous solutions may be used in combination of two or more.
- the concentration of ammonia water is preferably 0.01 to 10N, particularly preferably 0.1 to 3N.
- Phosphoric acids to be mixed with the eluate of 5-aminolevulinic acid include general formula (III)
- phosphoric acids include phosphoric acid; methyl phosphoric acid, ethyl phosphoric acid, n-butyl phosphoric acid, 2-ethylhexyl phosphoric acid, hexadecyl phosphoric acid, benzyl phosphoric acid, oleyl phosphoric acid, and phenyl phosphoric acid.
- Phosphoric acid monoesters Phosphoric acid diesters such as dimethyl phosphoric acid, jetyl phosphoric acid, di-n-butyl phosphoric acid, di (2-ethylhexyl) phosphoric acid, dihexadecyl phosphoric acid, dibenzyl phosphoric acid, dioleyl phosphoric acid, diphenylphosphoric acid Methylphosphoric acid, ethylphosphoric acid, oleylphosphoric acid, phenolic acid, dimethylphosphoric acid, jetylphosphoric acid, di-n-butylphosphoric acid, di (2-ethylhexyl) phosphoric acid, dihexadecylphosphoric acid, dibenzylphosphoric acid, Dioleyl phosphoric acid or diphenyl-phosphoric acid is particularly preferred. Moreover, hypophosphorous acid or phosphorous acid can also be used conveniently.
- the phosphoric acids may be either hydrates or salts, and those dissolved or dispersed in a suitable solvent can be preferably used.
- the amount of phosphoric acid mixed is preferably 1 to 5000 times the molar amount, more preferably 1 to 500 times the molar amount of the 5-aminolevulinic acid elution amount assumed from the adsorbed 5-aminolevulinic acid amount, A molar amount of 1 to 50 times is particularly preferable.
- the amount of 5-aminolevulinic acid adsorbed is assumed.
- the expected amount of 5-aminolevulinic acid elution varies depending on the type of cation exchange resin and the flow rate of the eluate, but usually adsorbed 5-aminolevulinic acid. 90-100% of the quantity.
- the nitric acid mixed with the 5-aminolevulinic acid eluate may be a salt or a solution dissolved in an appropriate solvent.
- the amount of nitric acid mixed is the same as the amount of phosphoric acid mixed above.
- the sulfonic acids mixed with the eluate of 5-aminolevulinic acid include P-toluenesulfonic acid, 2,4-dimethylphenolsulfonic acid, 2,5-dimethylphenolsulfonic acid, 3,5-dimethylphenol. -Sulfuronic acid, 2,4,6-trimethylphenol sulfonic acid and the like, and p-toluenesulfonic acid, 2,4-dimethylphenolsulfonic acid or 2,5-dimethylphenolsulfonic acid is particularly preferable.
- the sulfonic acids may be either hydrates or salts, and those dissolved or dispersed in an appropriate solvent can be preferably used.
- the mixing amount of the sulfonic acids is the same as the mixing amount of the phosphoric acids.
- Examples of the solvent include water; dimethyl sulfoxide; alcohols such as methanol, ethanol, propanol, isopropanol, n-butanol and isobutanol; ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ -dimethylacetamide, etc.
- Amide type; pyridine type and the like are mentioned, and water, methanol or ethanol are particularly preferred, with water, dimethyl sulfoxide, methanol or ethanol being preferred.
- Two or more solvents may be mixed and used.
- the poor solvent is not particularly limited as long as it precipitates a solid.
- a solvent include alcohols such as methanol, ethanol, propanol, isopropanol, ⁇ -butanol, and isobutanol; Ethers such as ether, diisopropyl ether, dioxane, tetrahydrofuran and dimethoxyethane; esters such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, and ⁇ -butyroratatone; ketones such as acetone and methylethyl ketone; acetonitrile, Examples include -tolyl-based compounds such as benzo-tolyl, and methyl acetate, ⁇ -butyrolatatone, acetone or acetonitrile is preferred, with methyl acetate, ethyl acetate, y-butyral rataton,
- the elution with an ion-containing aqueous solution and the mixing temperature of the eluate and phosphoric acid, nitric acid or sulfonic acid are -20 to 60 ° C in a state where the eluate and phosphoric acid, nitric acid or sulfonic acid are not solidified. -10-30 ° C is particularly preferred.
- the 5-aminolevulinic acid salt of the present invention includes those in which the amino group of 5-aminolevulinic acid is protected with an acyl group, or 1,3-dioxo-1,3-dihydro-isoindole-2 in the amino group.
- a 5-aminolevulinic acid power in which the amino group is protected by a hydrolyzable protecting group, such as a protecting group bonded to a -yl type molecular skeleton, may also be produced.
- the 5-aminorephosphate of the present invention can be produced by a method other than the present invention, that is, 2-phenyl-4- (
- phosphoric acids such as 5-aminolevulinic acid hydrochloride, nitric acid, and salts other than sulfonic acids with the desired phosphoric acid in a solvent.
- phosphoric acids those of the above general formula (ii) can be used, and nitric acid, sulfonic acids and reaction solvents described above can be used.
- 5-aminolevulinic acid salt does not feel odor compared to 5-aminolevulinic acid hydrochloride.
- 5-aminolevulinic acid phosphate is irritating to the skin and tongue.
- mutagenicity is not recognized.
- it has excellent permeability to animal skin and plant epidermis. Therefore, 5-aminolevulinic acid salt, preferably 5-aminolevulinic acid phosphate, is useful as a photodynamic therapy or a photodynamic diagnostic agent in animals including humans, similarly to 5-aminolevulinic acid hydrochloride.
- the photodynamic therapy or diagnostic agent include those for cancer, infection, rheumatism, thrombus, acne and the like.
- 5-aminolevulinic acid salt When 5-aminolevulinic acid salt is used as a photodynamic therapeutic agent or diagnostic agent, it can be used under known conditions. Specifically, JP 2001-501970 ( 1 ⁇ ⁇ 09873 0242), JP-T 4-500770 publication (WO9lZ01727), JP-T 2005-5050 publication (WO2003Z01265), JP-T 2004-506005 publication (WO2002Z013788), JP-T 2001-518498 publication (W099Z17764), The prescription and method disclosed in JP-T 8-507755 (W 094/17797) may be used.
- the disease can be treated photodynamically by administering an effective amount of 5-aminolevulinate to animals (including humans) and irradiating with light.
- the disease can be diagnosed photodynamically by detecting the fluorescence of the disease site.
- the composition for photodynamic therapy or photodynamic diagnosis containing 5-aminolevulinate can be made into a dosage form such as an external preparation for skin, an injection, an oral preparation, and a suppository.
- a pharmaceutically acceptable carrier can be used.
- the carrier water, a binder, a disintegrant, a dissolution accelerator, a lubricant, a filler, an excipient and the like are used.
- the dose varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but is usually 10 mg to 10 g per 1 kg body weight per adult, and more preferably 100 mg. In the range of ⁇ lg, once a day force is also administered several times.
- 5-aminolevulinic acid salt when used for, for example, a plant, it may contain a fertilizer component generally used.
- the fertilizer component include material strength disclosed in JP-A-4 338305 (US Pat. No. 5,298,482, EP-A-0514776).
- 5-Aminolevulinate is also useful as a plant activator. When used as a plant activator, it may be used under known conditions, specifically, JP-A-4-33830.
- examples of the plant activator include a foliar treatment agent and a soil treatment agent. Also, it can be absorbed before planting or cutting, or it can be soaked in water during hydroponics! / Take it! /.
- L particularly 50 to 300 L.
- Aminolevulinic acid salt is preferably contained in a concentration of 1 to 1,000 ppm, particularly 10 to 500 ppm, and 10 to 100 L, particularly 50 to 300 L, per 10 are used. It is preferable to use approximately the same amount during hydroponics cultivation.
- the target plants include cereals, vegetables, fruit berries, flower buds, coconut trees, beans, and potatoes.
- Odor was evaluated in the same manner as in Example 3 except that an aqueous solution and a solid of 5-aminolevulinic acid hydrochloride were used.
- the aqueous solution of 5-aminolevulinic acid hydrochloride was the same as the 5-aminolevulinic acid and phosphate ion concentration of the aqueous solution of 5-aminolevulinic acid phosphate of Example 1.
- the 5-aminolevulinic acid and the salt chloride ion concentration were prepared with a solid of 5 aminolevulinic acid hydrochloride, hydrochloric acid and ion-exchanged water so as to have the same molar concentration. The results are shown in Table 1.
- Odor was evaluated in the same manner as in Example 3 except that an aqueous solution in which 0.5 g of 5-aminolevulinic acid phosphate was dissolved in 1 mL of water was used. The results are shown in Table 2.
- Odor was evaluated in the same manner as in Example 3 except that an aqueous solution in which 0.5 g of 5-aminolevulinic acid hydrochloride was dissolved in 1 mL of water was used. The results are shown in Table 2.
- the aqueous solution of 5-aminolevulinic acid phosphate was stronger than that of the aqueous solution of 5-aminolevulinic acid hydrochloride. Odor countermeasures and corrosive gas countermeasures necessary for the production of an aqueous solution of 5-aminolevulinic acid hydrochloride have been simplified, making handling easier. Also, the solid of 5-aminolevulinic acid phosphate showed no odor compared to the solid of 5-aminolevulinic acid hydrochloride, and handling such as weighing and sealing was easier.
- Example 3 The power of 5 subjects The solid of 5-aminolevulinic acid phosphate obtained in Example 1 was directly placed on the tongue, and the taste was evaluated according to the following criteria. The results are shown in Table 3.
- Tests are based on “Standards for mutagenicity tests using microorganisms” (Ministry of Labor Notification No. 77 of 1988) (partially revised by Ministry of Labor Notification No. 67 of 1997) and “Tests on New Chemical Substances, etc.” Conforms to the “Reversion Mutation Test Using Bacteria” in “Methods” (November 21, 2003: Yakuhoku No. 1121002, No. 2, 2003 / November 13, 2003, Kanbo No. 031121002) And went.
- AF-2 2- (2- furyl) -3- (5-nitro D-2-furyl) Akuriruamito ', aN 3: Sodium ⁇ sheet'bets', ICR - 191: 6- click Rabbit - 9- [3 -(2-tap): tyramine)-pu bilamino] -2-Nutoxy-N-Acrisini dihydrochloride, 2-AA: 2-aminoanthracene
- test was conducted in accordance with OECD Guideline No.423 “Acute Oral Toxicity Acute Toxicity Rating Method” (adopted on December 7 , 2001).
- a group of 3 fasted female rats (Sprague— Dawley CD-type) was treated with 5-aminolevulinic acid phosphate at a dose of 300 mg / kg body weight.
- Yet another fasted group of female rats was treated with a dose of 2000 mg / kg body weight. Observation was continued for 2 weeks after administration.
- the test was conducted in accordance with OECD guideline No. 404 “Acute skin irritation Z corrosion test” (adopted July 17, 1992) and EU Commission Directive 92 69ZEEC B4 method acute toxicity (skin irritation).
- the permeability was measured in the same manner as in Example 10 except that 5-aminolevulinic acid hydrochloride was used instead of 5-aminolevulinic acid phosphate.
- Example 2 The 5-aminolevulinic acid phosphate obtained in Example 1 was dissolved in ion-exchanged water to obtain a predetermined concentration in the table.
- a spreading agent (“Approach” manufactured by Maruwa Biochemical Co., Ltd.) was added to the solution so that the concentration was 0.1% by weight.
- the pH was adjusted using phosphoric acid.
- a 5-aminolevulinic acid hydrochloride aqueous solution was prepared in the same manner except that the above 5-aminolevulinic acid phosphate was changed to 5-aminolevulinic acid hydrochloride and pH-adjusted phosphoric acid was hydrochloric acid.
- Plant vitality effect Prepare 12 pieces of magnetic pots with an inner diameter of 12cm and 600g of volcanic ash soil, and a plant with a single cypress growing up to a height of 15cm in a pot for a constant temperature environment of 20 ° C. Every other day, the foliage spray treatment with the following spray solution was performed. The state of the leaves after 21 days was observed. The results are summarized in Table 10.
- 5-Aminolevulinic acid phosphate exhibited a plant growth promoting effect equivalent to or better than that of 5-aminolevulinic acid hydrochloride.
- 5-aminolevulinic acid phosphate showed the same or higher salt resistance improvement effect as 5-aminolevulinic acid hydrochloride.
- Aqueous solution comprising 0.5mmolZL), D. flow (1.5mLZmin), E. Saburessa (ASRS (recycle Rumodo, current 5 OMA)), F. sample introduction amount (2 5 ⁇ L), G. the temperature of a thermostat ( 35 degrees), ⁇ ⁇ ⁇ .
- ASRS cycle Rumodo, current 5 OMA
- Example 5 Five subjects directly sniffed the aqueous solution of 5-aminorepric acid nitrate prepared in Example 16 (mixed solution of eluent of column force and nitric acid) and its solid odor, and carried out in the same manner as in Example 3. Odor was evaluated. The results are shown in Table 13. [0091] (Comparative Example 5)
- Example 17 5 Odor was evaluated in the same manner as in Example 17 except that an aminolevulinic acid hydrochloride aqueous solution and a solid were used.
- the aqueous solution of 5-aminolevulinic acid hydrochloride had the same 5-aminolevulinic acid and nitrate ion concentrations as the 5-aminolevulinic acid nitrate aqueous solution of Example 16, respectively. It was prepared with 5 aminolevulinic acid hydrochloride solid, hydrochloric acid and ion-exchanged water so as to have a molar concentration. The results are shown in Table 13.
- Odor was evaluated in the same manner as in Example 17 except that an aqueous solution in which 0.5 g of 5-aminolevulinic acid nitrate was dissolved in 1 mL of water was used. The results are shown in Table 14.
- Odor was evaluated in the same manner as in Example 17 except that an aqueous solution in which 0.5 g of 5-aminolevulinic acid hydrochloride was dissolved in 1 mL of water was used. The results are shown in Table 14.
- the aqueous solution of 5-aminolevulinic acid nitrate showed no odor as compared with the aqueous solution of 5-aminolevulinic acid hydrochloride. Odor and corrosive gas measures necessary for the production of 5-aminolevulinic acid hydrochloride aqueous solution are unnecessary, and handling is easier. I got it. Also, the odor of the solid of 5-aminolevulinic acid nitrate was not recognized as compared with the solid of 5-aminolevulinic acid hydrochloride, and handling such as weighing and sealing was easier.
- 5-Aminolevulinic acid nitrate 0.5 g and silver nitrate 0.5 g were dissolved in 10 mL of ion-exchanged water, allowed to stand for 5 minutes, and the state of the liquid was observed. No precipitation was observed.
- the solution was allowed to stand for 5 minutes and the state of the liquid was observed. The occurrence of precipitation was observed.
- a magnetic pot with an inner diameter of 12 cm was filled with 600 g of field soil, 12 seeds of white radish seeds were sown, covered with 5 mm, and grown in a greenhouse. The foliage was sprayed once a day with the indicated spray liquid. The state of the leaves after 21 days was observed. The results are summarized in Table 15. The judgment criteria are the same as in Example 13.
- the 5-aminolevulinic acid nitrate obtained in Example 16 was dissolved in ion-exchanged water to obtain the predetermined concentrations shown in Table 16.
- a spreading agent (“Approach” manufactured by Maruwa Biochemical Co., Ltd.) was added to the solution so that the concentration was 0.1% by weight.
- the pH was adjusted with nitric acid.
- 1-mL of 5-aminolevulinic acid nitrate is added to 100 mL of the sterile culture shown in Table 17 (Composition of culture).
- chlorella Chlorella sp.
- reciprocal shaking culture was performed at 30 ° C. under aerobic dark conditions to measure the amount of cells (OD660 nm).
- Inoculate chlorella Cholecium sp.
- Table 17 components of culture solution
- Measurement conditions were: A. Separation column (IonPac AS12A manufactured by Nippon Dionetas), B. Guard column (IonPac AG 12 A manufactured by Nippon Dionetas), C. Eluent (Na CO: 3.0mmol / L, NaHCO
- Aqueous solution consisting of 0.5 mmol ZL), D. Flow rate (1.5 mLZmin), E. Sublesser (ASRS (recycle mode, current value 50 mA)), F. Sample introduction volume (25 ⁇ L), G. Temperature chamber temperature (35 ° C) ), V. By detector (electric conductivity detector).
- the collected eluate was mixed with 81.72 g (430 mmol) of P-toluenesulfonic acid monohydrate and concentrated by an evaporator.
- 400 mL of acetone was added, stirred vigorously with a stirrer, and allowed to stand at 4 ° C for 16 hours.
- the precipitated solid was collected by suction filtration and washed with 400 mL of acetone.
- the obtained solid was dried under reduced pressure for 12 hours to obtain 47.78 g (158 mmol) of the desired product.
- the physical property data is shown below.
- Example 23 Five subjects directly smelled the 5 aminolevulinic acid P-toluenesulfonate aqueous solution (mixed solution of eluate from the column and P-toluenesulfonic acid) prepared in Example 23 and the solid odor. The odor was evaluated as in Example 3. The results are shown in Table 19.
- Example 25 5 Odor was evaluated in the same manner as in Example 24 except that an aminolevulinic acid hydrochloride aqueous solution and a solid were used.
- the aqueous solution of 5-aminolevulinic acid hydrochloride was the 5-aminolevulinic acid and P-toluenesulfonic acid ion concentration of 5-aminolevulinic acid P-toluenesulfonic acid aqueous solution of Example 23, and 5-aminolevulinic acid and hydrochloride. It was prepared with a solid of 5-aminolevulinic acid hydrochloride, hydrochloric acid and ion-exchanged water so that the chloride ion concentration would be the same molar concentration. The results are shown in Table 19.
- the odor was evaluated in the same manner as in Example 24 except that an aqueous solution in which 0.5 g of 5-aminolevulinic acid P-toluenesulfonate was dissolved in 1 mL of water was used. The results are shown in Table 20.
- Odor was evaluated in the same manner as in Example 24 except that an aqueous solution in which 0.5 g of 5-aminolevulinic acid hydrochloride was dissolved in 1 mL of water was used. The results are shown in Table 20.
- the melting point was measured with a melting point meter.
- 5-Aminolevulinic acid P-toluenesulfonate and 50 mg of 5-aminolevulinic acid hydrochloride were heat sterilized (121 ° C, 20 minutes, 1.5 kgf / cm 2 ). After confirming that there was no change in weight before and after sterilization, the degree of degradation of 5-aminolevulinic acid before and after sterilization was confirmed by the method described in the literature (Clin. Chem. 36/8, 1494 (1990)). . The results are shown in Table 22.
- 5-aminolevulinic acid P-toluenesulfonate was found to be less degradable in high-temperature heat sterilization treatment than 5-aminolevulinic acid hydrochloride.
- 5-Aminolevulinic acid P-toluenesulfonate 0.5 g and silver nitrate 0.5 g were dissolved in 10 mL of ion-exchanged water, allowed to stand for 5 minutes, and the state of the liquid was observed. The occurrence of precipitation was not observed. Dissolve 0.5 g of 5-aminolevulinic acid hydrochloride and 0.5 g of silver nitrate in 10 mL of ion-exchanged water.
- the solution was allowed to stand for 5 minutes and the state of the liquid was observed. The occurrence of precipitation was observed.
- a magnetic pot with an inner diameter of 12 cm was filled with 600 g of field soil, 12 seeds of white radish seeds were sown, covered with 5 mm, and grown in a greenhouse. The foliage was sprayed once a day with the indicated spray liquid. The state of the leaves after 21 days was observed. The results are summarized in Table 23. The judgment criteria are the same as in Example 13.
- the 5-aminolevulinic acid P-toluenesulfonate obtained in Example 23 was dissolved in ion-exchanged water to obtain the predetermined concentrations shown in Table 24.
- a spreading agent (“Approach Bl” manufactured by Maruwa Biochemical Co., Ltd.) was added to the solution so that the concentration was 0.1% by weight.
- the pH was adjusted using P-toluenesulfonic acid.
- the above 5-aminolevulinic acid P-toluenesulfonate was prepared in the same manner except that 5-aminolevulinic acid hydrochloride was used, and P-toluenesulfonic acid was used as hydrochloric acid.
- the fruit of the apple “Fuji” came to fruition, and 2 L of the prepared liquid was sprayed onto 3 main branches that were not yet colored red (September 15). Approximately two months later (November 6), apples were harvested and the coloration was examined. For color measurement, a color saturation meter CR-200 manufactured by Minolta Co., Ltd. was used. The results are shown in Table 24.
- P-toluenesulfone 200 ppm (pH 4.9) 42.36 30.93 14.34 Acid salt 200 ppm (pH 2.0)---
- Measurement conditions are: A. Separation column (IonPac AS 12 A, manufactured by Nippon Dionetas), B. Guard column (IonPac AG 12 A, manufactured by Nippon Dionetas), C. Eluent (Na 2 CO 3: 3.0 mmol / L, NaHCO 3
- Aqueous solution consisting of 0.5 mmol ZL), D. Flow rate (1.5 mLZmin), E. Sabressa (ASRS (recycle mode, current value 50 mA)), F. Sample introduction volume (25 ⁇ L), G. Temperature chamber temperature (35. C), H. By detector (electric conductivity detector).
- the 5-aminolevulinic acid salt of the present invention is an easy-to-handle substance because it has no odor and no irritating odor.
- it since it is hypoallergenic to the skin and tongue and also has good permeability to the skin and the like, it is useful as a photodynamic therapeutic or diagnostic agent for a composition containing it. Furthermore, it has high temperature resistance with a high decomposition point compared with hydrochloride. According to the production method of the present invention, 5-aminolevulinic acid salt can be produced simply and efficiently.
- the salt and salt ion concentration in aqueous solution is low, chlorine damage is unlikely to occur when administered to plants.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pest Control & Pesticides (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117013838A KR101267893B1 (ko) | 2004-03-30 | 2005-03-28 | 5-아미노레불린산 설폰산염 및 이의 제조방법 |
US10/594,923 US8173839B2 (en) | 2004-03-30 | 2005-03-28 | 5-aminolevulinic acid salt, process for producing the same and use thereof |
AT05727585T ATE493382T1 (de) | 2004-03-30 | 2005-03-28 | 5-aminolevulinsäure-phosphatsalz, verfahren zu dessen herstellung und dessen verwendung |
DK05727585.1T DK1731500T3 (da) | 2004-03-30 | 2005-03-28 | 5-aminolevulinsyre-phosphatsalt, fremgangsmåde til fremstilling deraf og anvendelse deraf |
KR1020067020140A KR101225462B1 (ko) | 2004-03-30 | 2005-03-28 | 5-아미노레불린산염, 이의 제조방법 및 이의 용도 |
AU2005232995A AU2005232995B2 (en) | 2004-03-30 | 2005-03-28 | 5-aminolevulinic acid salt, process for producing the same and use thereof |
DE602005025614T DE602005025614D1 (de) | 2004-03-30 | 2005-03-28 | 5-aminolevulinsäure-phosphatsalz, verfahren zu dessen herstellung und dessen verwendung |
CN2005800107065A CN1942430B (zh) | 2004-03-30 | 2005-03-28 | 5-氨基乙酰丙酸盐、其制备方法及其用途 |
KR1020127030026A KR101312982B1 (ko) | 2004-03-30 | 2005-03-28 | 5-아미노레불린산염, 이의 제조방법 및 이의 용도 |
EP05727585A EP1731500B1 (en) | 2004-03-30 | 2005-03-28 | 5-aminolevulinic acid phosphate salt, process for producing the same and use thereof |
PL05727585T PL1731500T3 (pl) | 2004-03-30 | 2005-03-28 | Sól fosforanowa kwasu 5-aminolewulinowego, sposób jej wytwarzania oraz jej zastosowanie |
CA2562170A CA2562170C (en) | 2004-03-30 | 2005-03-28 | 5-aminolevulinic acid salt, process for producing the same and use thereof |
NO20064373A NO335109B1 (no) | 2004-03-30 | 2006-09-27 | 5-aminolevulinsyresalt, preparat omfattende slike, fremgangsmåte for dets fremstilling og anvendelse derav. |
US13/418,465 US8471061B2 (en) | 2004-03-30 | 2012-03-13 | 5-aminolevulinic acid salt, process for producing the same and use thereof |
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-099670 | 2004-03-30 | ||
JP2004099672 | 2004-03-30 | ||
JP2004-099672 | 2004-03-30 | ||
JP2004099671 | 2004-03-30 | ||
JP2004099670 | 2004-03-30 | ||
JP2004-099671 | 2004-03-30 | ||
JP2004345661 | 2004-11-30 | ||
JP2004-345661 | 2004-11-30 | ||
JP2005051218A JP4630087B2 (ja) | 2004-03-30 | 2005-02-25 | 5−アミノレブリン酸硝酸塩及びその製造方法 |
JP2005-051218 | 2005-02-25 | ||
JP2005051217A JP4417865B2 (ja) | 2004-03-30 | 2005-02-25 | 5−アミノレブリン酸リン酸塩、その製造方法及びその用途 |
JP2005-051217 | 2005-02-25 | ||
JP2005-051216 | 2005-02-25 | ||
JP2005051216A JP4719483B2 (ja) | 2004-03-30 | 2005-02-25 | 5−アミノレブリン酸スルホン酸塩の製造方法 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/594,923 A-371-Of-International US8173839B2 (en) | 2004-03-30 | 2005-03-28 | 5-aminolevulinic acid salt, process for producing the same and use thereof |
US13/418,465 Continuation US8471061B2 (en) | 2004-03-30 | 2012-03-13 | 5-aminolevulinic acid salt, process for producing the same and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005100300A1 true WO2005100300A1 (ja) | 2005-10-27 |
Family
ID=35149925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005765 WO2005100300A1 (ja) | 2004-03-30 | 2005-03-28 | 5-アミノレブリン酸塩、その製造方法及びその用途 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8173839B2 (ja) |
EP (1) | EP1731500B1 (ja) |
KR (3) | KR101312982B1 (ja) |
CN (3) | CN101885736B (ja) |
AT (1) | ATE493382T1 (ja) |
AU (1) | AU2005232995B2 (ja) |
CA (1) | CA2562170C (ja) |
DE (1) | DE602005025614D1 (ja) |
DK (1) | DK1731500T3 (ja) |
NO (1) | NO335109B1 (ja) |
PL (1) | PL1731500T3 (ja) |
PT (1) | PT1731500E (ja) |
WO (1) | WO2005100300A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007238577A (ja) * | 2006-03-13 | 2007-09-20 | Cosmo Oil Co Ltd | アミノ酸リン酸類塩の製造方法 |
JP2007530523A (ja) * | 2004-03-26 | 2007-11-01 | フォトキュア エイエスエイ | 5−アミノレブリン酸又はその誘導体の酸付加塩 |
WO2008020532A1 (en) | 2006-08-15 | 2008-02-21 | Cosmo Oil Co., Ltd. | Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof |
EP1927586A1 (en) * | 2005-09-21 | 2008-06-04 | Cosmo Oil Co., Ltd. | Process for producing 5-aminolevulinic acid hydrochloride |
JP2010053104A (ja) * | 2008-08-29 | 2010-03-11 | Cosmo Oil Co Ltd | 植物の病原菌感染抑制剤及び病原菌感染抑制方法 |
JP2014189492A (ja) * | 2013-03-26 | 2014-10-06 | Cosmo Oil Co Ltd | 5−アミノレブリン酸リン酸塩の製造方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070225518A1 (en) * | 2006-03-22 | 2007-09-27 | Zvi Malik | 5-Aminolevulinic acid salts and their use |
EP2585111A1 (en) * | 2010-06-23 | 2013-05-01 | Photocure ASA | Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent |
EP2657346B1 (en) | 2010-12-24 | 2017-08-23 | ARKRAY, Inc. | Method for detecting cancer cell |
EP2722041B1 (en) * | 2011-06-16 | 2018-10-24 | SBI Pharmaceuticals Co., Ltd. | Therapeutic agent for allergic rhinitis |
US9957469B2 (en) * | 2014-07-14 | 2018-05-01 | Versum Materials Us, Llc | Copper corrosion inhibition system |
CN112010772A (zh) | 2016-01-26 | 2020-12-01 | 赵鸣 | 5-氨基酮戊酸及其衍生物的盐化合物和应用 |
EP4349401A1 (en) | 2019-02-13 | 2024-04-10 | Alpheus Medical, Inc. | Non-invasive sonodynamic therapy |
CN113293123B (zh) * | 2021-07-15 | 2023-06-16 | 山东深海生物科技股份有限公司 | 5-氨基乙酰丙酸在促进凯氏拟小球藻生长中的应用 |
CN114920598B (zh) * | 2022-04-19 | 2023-06-06 | 烟台泓源生物肥料有限公司 | 一种生物肥料及其制备方法和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60139656A (ja) * | 1983-12-27 | 1985-07-24 | Ajinomoto Co Inc | リジン製造法 |
JPH04338305A (ja) * | 1991-05-14 | 1992-11-25 | Cosmo Sogo Kenkyusho:Kk | 植物成長促進剤 |
JPH05310657A (ja) * | 1992-05-12 | 1993-11-22 | Mitsui Toatsu Chem Inc | ペプチド類からアミノ酸を回収する方法 |
JPH06294797A (ja) * | 1992-05-14 | 1994-10-21 | N O K Ii G & G Oputo Electron Kk | デルタアミノレブリン酸類の微量定量法 |
JPH0753311A (ja) * | 1993-08-19 | 1995-02-28 | Cosmo Sogo Kenkyusho:Kk | 植物の蓚酸含量低減剤 |
JPH08151304A (ja) * | 1994-11-28 | 1996-06-11 | Cosmo Sogo Kenkyusho:Kk | 植物の耐塩性向上剤 |
WO1997003042A1 (fr) * | 1995-07-12 | 1997-01-30 | Mitsubishi Chemical Corporation | Acide 2,2-dideutero-5-aminolevulinique |
JP2001151614A (ja) * | 1990-05-03 | 2001-06-05 | Board Of Trustees Of The Univ Illinois | 除草および殺虫組成物並びに除草および殺虫方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04217650A (ja) | 1990-10-29 | 1992-08-07 | Japan Tobacco Inc | δ−アミノレブリン酸の酸付加塩の製造方法 |
DE69109444T2 (de) | 1990-10-29 | 1995-09-28 | Japan Tobacco Inc | Ein Verfahren zur Herstellung von einem säureergänzenden Salz von delta-Aminolevulinsäure. |
JP2997979B2 (ja) | 1993-01-20 | 2000-01-11 | 株式会社コスモ総合研究所 | 5−アミノレブリン酸の製造方法 |
JP2887555B2 (ja) | 1993-08-19 | 1999-04-26 | 株式会社コスモ総合研究所 | 植物の硝酸態窒素含量低減剤 |
US5489572A (en) * | 1993-08-19 | 1996-02-06 | Cosmo Research Institue | Methods for reducing nitrate nitrogen and oxalic acids contents nin plants |
DE19852245A1 (de) * | 1998-11-12 | 2000-05-18 | Asat Ag Applied Science & Tech | 5-Aminolävulinsäure-Nanoemulsion |
GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
-
2005
- 2005-03-28 WO PCT/JP2005/005765 patent/WO2005100300A1/ja active Application Filing
- 2005-03-28 AU AU2005232995A patent/AU2005232995B2/en active Active
- 2005-03-28 KR KR1020127030026A patent/KR101312982B1/ko active IP Right Grant
- 2005-03-28 AT AT05727585T patent/ATE493382T1/de active
- 2005-03-28 EP EP05727585A patent/EP1731500B1/en active Active
- 2005-03-28 CN CN2010102153643A patent/CN101885736B/zh active Active
- 2005-03-28 CN CN2010102153906A patent/CN101863788B/zh active Active
- 2005-03-28 PT PT05727585T patent/PT1731500E/pt unknown
- 2005-03-28 CN CN2010102154650A patent/CN101885692B/zh active Active
- 2005-03-28 US US10/594,923 patent/US8173839B2/en active Active
- 2005-03-28 DE DE602005025614T patent/DE602005025614D1/de active Active
- 2005-03-28 CA CA2562170A patent/CA2562170C/en active Active
- 2005-03-28 KR KR1020117013838A patent/KR101267893B1/ko active IP Right Grant
- 2005-03-28 KR KR1020067020140A patent/KR101225462B1/ko active IP Right Grant
- 2005-03-28 DK DK05727585.1T patent/DK1731500T3/da active
- 2005-03-28 PL PL05727585T patent/PL1731500T3/pl unknown
-
2006
- 2006-09-27 NO NO20064373A patent/NO335109B1/no unknown
-
2012
- 2012-03-13 US US13/418,465 patent/US8471061B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60139656A (ja) * | 1983-12-27 | 1985-07-24 | Ajinomoto Co Inc | リジン製造法 |
JP2001151614A (ja) * | 1990-05-03 | 2001-06-05 | Board Of Trustees Of The Univ Illinois | 除草および殺虫組成物並びに除草および殺虫方法 |
JPH04338305A (ja) * | 1991-05-14 | 1992-11-25 | Cosmo Sogo Kenkyusho:Kk | 植物成長促進剤 |
JPH05310657A (ja) * | 1992-05-12 | 1993-11-22 | Mitsui Toatsu Chem Inc | ペプチド類からアミノ酸を回収する方法 |
JPH06294797A (ja) * | 1992-05-14 | 1994-10-21 | N O K Ii G & G Oputo Electron Kk | デルタアミノレブリン酸類の微量定量法 |
JPH0753311A (ja) * | 1993-08-19 | 1995-02-28 | Cosmo Sogo Kenkyusho:Kk | 植物の蓚酸含量低減剤 |
JPH08151304A (ja) * | 1994-11-28 | 1996-06-11 | Cosmo Sogo Kenkyusho:Kk | 植物の耐塩性向上剤 |
WO1997003042A1 (fr) * | 1995-07-12 | 1997-01-30 | Mitsubishi Chemical Corporation | Acide 2,2-dideutero-5-aminolevulinique |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530523A (ja) * | 2004-03-26 | 2007-11-01 | フォトキュア エイエスエイ | 5−アミノレブリン酸又はその誘導体の酸付加塩 |
US8692014B2 (en) | 2004-03-26 | 2014-04-08 | Photocure Asa | Acid addition salts of 5-aminolevulinic acid or its derivatives |
EP2402306A1 (en) * | 2005-09-21 | 2012-01-04 | Cosmo Oil Co., Ltd. | Method for producing 5-aminolevulinic acid hydrochloride |
US8148574B2 (en) | 2005-09-21 | 2012-04-03 | Cosmo Oil Co., Ltd. | Method for producing 5-aminolevulinic acid hydrochloride |
EP1927586A1 (en) * | 2005-09-21 | 2008-06-04 | Cosmo Oil Co., Ltd. | Process for producing 5-aminolevulinic acid hydrochloride |
NO338789B1 (no) * | 2005-09-21 | 2016-10-17 | Cosmo Ala Co Ltd | Fremgangsmåte for fremstilling av 5-aminolevulinsyreoppløsning |
EP1927586A4 (en) * | 2005-09-21 | 2010-04-14 | Cosmo Oil Co Ltd | PROCESS FOR PRODUCTION OF 5-AMINOLEVULINIC ACID CHLORHYDRATE |
US8207376B2 (en) | 2006-03-13 | 2012-06-26 | Cosmo Oil Co., Ltd. | Method for producing amino acid phosphates |
JP2007238577A (ja) * | 2006-03-13 | 2007-09-20 | Cosmo Oil Co Ltd | アミノ酸リン酸類塩の製造方法 |
KR101078896B1 (ko) * | 2006-03-13 | 2011-11-01 | 코스모세키유 가부시키가이샤 | 아미노산인산류 염의 제조 방법 |
CN101346347B (zh) * | 2006-03-13 | 2013-07-31 | 克斯莫石油株式会社 | 氨基酸磷酸盐的制备方法 |
WO2007119302A1 (ja) | 2006-03-13 | 2007-10-25 | Cosmo Oil Co., Ltd. | アミノ酸リン酸類塩の製造方法 |
NO339369B1 (no) * | 2006-03-13 | 2016-12-05 | Cosmo Ala Co Ltd | Fremgangsmåte for fremstilling av fosfater av en aminosyre eller en ester derav |
US8158821B2 (en) | 2006-08-15 | 2012-04-17 | Cosmo Oil Co., Ltd. | Crystal of 5-aminolevulinic acid phosphate and process for producing the same |
WO2008020532A1 (en) | 2006-08-15 | 2008-02-21 | Cosmo Oil Co., Ltd. | Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof |
CN101472879B (zh) * | 2006-08-15 | 2013-11-13 | 克斯莫石油株式会社 | 5-氨基乙酰丙酸磷酸盐的新型晶体及其制备方法 |
NO339472B1 (no) * | 2006-08-15 | 2016-12-12 | Cosmo Ala Co Ltd | Ny krystall av 5-aminolevulinsyrefosfat og fremgangsmåte for fremstilling derav |
JP2010053104A (ja) * | 2008-08-29 | 2010-03-11 | Cosmo Oil Co Ltd | 植物の病原菌感染抑制剤及び病原菌感染抑制方法 |
JP2014189492A (ja) * | 2013-03-26 | 2014-10-06 | Cosmo Oil Co Ltd | 5−アミノレブリン酸リン酸塩の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101312982B1 (ko) | 2013-10-01 |
AU2005232995B2 (en) | 2010-01-28 |
PT1731500E (pt) | 2011-02-01 |
US20070203027A1 (en) | 2007-08-30 |
EP1731500A4 (en) | 2007-04-25 |
KR101225462B1 (ko) | 2013-01-24 |
AU2005232995A1 (en) | 2005-10-27 |
CN101863788B (zh) | 2012-05-30 |
CN101885736B (zh) | 2012-10-03 |
DK1731500T3 (da) | 2011-02-07 |
DE602005025614D1 (de) | 2011-02-10 |
CN101863788A (zh) | 2010-10-20 |
CA2562170A1 (en) | 2005-10-27 |
EP1731500A1 (en) | 2006-12-13 |
US8173839B2 (en) | 2012-05-08 |
US8471061B2 (en) | 2013-06-25 |
KR20110074797A (ko) | 2011-07-01 |
CN101885692A (zh) | 2010-11-17 |
PL1731500T3 (pl) | 2011-06-30 |
EP1731500B1 (en) | 2010-12-29 |
KR101267893B1 (ko) | 2013-05-27 |
KR20120130348A (ko) | 2012-11-30 |
US20120172227A1 (en) | 2012-07-05 |
CN101885692B (zh) | 2011-11-02 |
NO335109B1 (no) | 2014-09-15 |
ATE493382T1 (de) | 2011-01-15 |
CA2562170C (en) | 2013-04-23 |
NO20064373L (no) | 2007-01-02 |
KR20070015528A (ko) | 2007-02-05 |
CN101885736A (zh) | 2010-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005100300A1 (ja) | 5-アミノレブリン酸塩、その製造方法及びその用途 | |
JP4417865B2 (ja) | 5−アミノレブリン酸リン酸塩、その製造方法及びその用途 | |
JP4719483B2 (ja) | 5−アミノレブリン酸スルホン酸塩の製造方法 | |
JP4630087B2 (ja) | 5−アミノレブリン酸硝酸塩及びその製造方法 | |
EP2053039B1 (en) | Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof | |
ES2355978T3 (es) | Sal de fosfato de ácido 5-aminolevulinico, proceso para producir la misma y uso de la misma. | |
EP3527575A1 (en) | Bis(oxymethyl)phosphinic acid and biogenic metal salts thereof as regulators of plant growth and development | |
JPS6119620B2 (ja) | ||
JP4526622B2 (ja) | 農園芸用種子消毒剤および種子の消毒方法 | |
JPS60166645A (ja) | 安息香酸誘導体、その製法並びに薬物、殺菌剤もしくは防腐剤としての使用法 | |
JP2007252248A (ja) | 結球促進剤 | |
PL230984B1 (pl) | Nowe sole organiczne z kationem trimetylosulfoniowym, sposób ich otrzymywania oraz zastosowanie jako środki ochrony roślin | |
CN114230454B (zh) | 没食子酸类天然活性成分的钙配合物及其合成方法和应用 | |
CN109970632B (zh) | 具有氮杂查尔酮结构的羟基吡啶酮衍生物及制备法和用途 | |
RU2298324C2 (ru) | Способ повышения урожайности подсолнечника | |
RU2460773C2 (ru) | Жидкая питательная среда для накопления высокоактивных метаболитов штаммом bacillus pumilus "пашков", обладающих ингибирующим действием в отношении бактерий, грибов и вирусов | |
PL238501B1 (pl) | Czwartorzędowe sole amoniowe o czynności herbicydowej | |
PL228326B1 (pl) | Argininowe sole fenoksykwasów, sposoby ich otrzymywania oraz zastosowanie jako herbicydy | |
PL230985B1 (pl) | Nowe trzeciorzędowe sole organiczne z kationem trimetylosulfoksoniowym, sposób ich otrzymywania oraz zastosowanie jako herbicydy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580010706.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2562170 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727585 Country of ref document: EP Ref document number: 1020067020140 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005232995 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005232995 Country of ref document: AU Date of ref document: 20050328 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005232995 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727585 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10594923 Country of ref document: US Ref document number: 2007203027 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10594923 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020117013838 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020127030026 Country of ref document: KR |